Abstract 223P
Background
Breast Cancer (BC) is the most common malignancy and the leading cause of cancer-related death in women. Pregnancy-Associated Breast Cancer (PABC) is defined as BC that is diagnosed during pregnancy or within one year of delivery. PABC is considered a more aggressive entity. This work intended to evaluate the characteristics and prognosis of PABC versus non-PABC in a young female cohort of our institution.
Methods
Retrospective analyses of our centre female population with invasive BC diagnosed from 2014 to 2020, with 40 years or less at the time of diagnosis. Data was collected from patients’ electronic clinical process and IBM SPSS® Statistics software (version 27) was used for statistical analysis. It was considered statistically significant if p<0,05.
Results
During this 7-year period, 59 patients were identified: 12 with PABC and 47 with non-PABC. In this last group, 4 had synchronous BC. The median age at diagnosis was 37 years (24-40), being lower in the PABC group (33,5) than in the non-PABC group (38) (p=0,021). When grouped by biological aggressiveness (triple negative or HER2 enriched versus luminal A or luminal B HER2 negative), there was a statistically significant difference, with 91,7% of PABC patients with triple negative/HER2 enriched subtype tumours versus 52,9% of the non-PABC patients (p=0,014). There were 66,7% patients with axillary lymph node metastasis in the PABC group and 58,8% in the non-PABC group (p=0,617). The median follow-up time was 20,51 months (4,57-80,93), with estimated rates of progression-free survival (PFS) and overall survival (OS) at 3 years in the total study population of 90% and 91%, respectively (medians not reached). PFS at 3 years was 78% in the PABC group and 94% in the non-PABC group (p=0,173). OS at 3 years was 75% in the PABC group and 93% in the non-PABC group (p=0,607).
Conclusions
Our data confirms the good prognosis associated to BC at younger ages and the association mentioned in literature of more aggressive tumour subtypes and higher rates of axillary lymph node metastasis with PABC. Although not statistically significant, a trend to worse PFS and OS was observed in the PABC group. The retrospective study design limits the interpretation of this data. A longer follow-up time and a bigger sample size are needed to support these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.